ASP Isotopes Inc. · NASDAQ:ASPI
ASP Isotopes — Investor Presentation (October 2023)
36 slides from ASP Isotopes's investor presentation, October 2023
Slide 1: Corporate Overview
Corporate Overview October 2023 © ASP Isotopes Inc. 1
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking Statements This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looki
Slide 3: ASP Isotopes: At a Glance
ASP Isotopes: At a Glance 1. Proven & Proprietary Technology ASPI's advanced technology platform leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Its innovative technology will enable the company to manufacture a diverse range of isotopes, which will ASP Isotope
Slide 4: Company History
Company History October 2021 • ASP Isotopes wins competitive auction for July 2022 March 2023 June 2023 December 2020 Klydon Large-scale Plant Acquisition of the Small-Scale ASP announces the ASP Secures $9m Supply Introduction to Klydon • Raised an additional $6 million and Plant enrichment facilit
Slide 5: Isotope Production is Essential for National and Global Security
Isotope Production is Essential for National and Global Security Isotopes have one of the most severely compromised supply chains of Historical Isotope any material in the world and are Critical to the following end markets. Market Producers1 Nuclear Power Europe Generation 15% Space Quantum Explora
Slide 6: What Is An Isotope?
What Is An Isotope? Molybdenum (Mo) has 7 stable isotopes, where Molybdenum-100 content in the natural mix is only 10%. Isotopes are like identical twins or triplets: very similar in most aspects, except for a few subtle differences. • Isotopes are two or more atoms of the same chemical element with
Slide 7: ASP Isotopes: Technology Highlights
ASP Isotopes: Technology Highlights 1. Cost-Effective Isotope enrichment facilities using ASP technology can be constructed at a fraction of capital cost and time vs. traditional isotope separation facilities. This technology has been refined for over 20 years through the South African Nuclear Enric
Slide 8: ASP Technology: Stationary Wall Centrifuge
ASP Technology: Stationary Wall Centrifuge Benefits of a Stationary Wall Centrifuge V 1. No moving parts vs. a conventional centrifuge 2. No unique materials are required 3. Cost-efficient at small scale 4. High Separation Efficiency Small Production Flexible Capacity Modules Deployment High Separat
Slide 9: Anticipated Milestones
Anticipated Milestones MARKET MILESTONES OPERATIONAL MILESTONES 1. Secure at least 2 additional supply agreements 1. Start commercial production of isotopes at our for isotopes critical for new technologies and enrichment facilities in South Africa. – Late 2023-Early healthcare. 2024 2. Generate suf
Slide 10: Isotopes of Interest
Isotopes of Interest Under Commercially Isotopes End-Market R&D Stage R&D Evaluation Construction Available Carbon-14 Pharma & Agrochem Silicon-28 Quantum Computing Germanium-70/72/74 Quantum Computing Available in Molybdenum-100 2H23 Nuclear Medicine Available in Molybdenum-98 2H23 Zinc- 67/68 Ytte
Slide 11: Isotope End Markets: Nuclear Medicine
Isotope End Markets: Nuclear Medicine ISOTOPES OF INTEREST 14C 99Tc 68Ga 67Cu 67Cu 177Lu END MARKET Carbon-Dating PET Scan imaging Oncology Oncology SPECT Scan Treatment Treatment Pharmacokinetic Imaging Oncology (Non-Hodgkin (Neuroendocrine Tracing Treatment lymphoma, Prostate Tumors NETs) Cancer,
Slide 12: Isotope End Markets: Carbon-14
Isotope End Markets: Carbon-14 (14C) A scientific technique used to track the passage of a Radiolabeling molecule. The technique incorporates a radioisotope ASPI’s Carbon-14 enrichment facility through a reaction, cell, organism, biological system, or metabolic pathway. Used as a radiolabeling compo
Slide 13: Isotope End Markets: Molybdenum-100 and Zinc-68
Isotope End Markets: Molybdenum-100 and Zinc-68 Imaging Agent Distribution Single-photon emission 99Tc computed tomography (SPECT) It is estimated that 80-85% of all Technetium-99 SPECT procedures utilize Global Market Size6 Technetium-998 99Tc Global Market Size7 $4.61B $4.17B Imaging Agent Distrib
Slide 14: Nuclear Medicine Supply Chain
Nuclear Medicine Supply Chain Current Mo99 Supply Chain Current Isotope Conversion Process ASP Isotope Conversion Process 99Mo 99Tc 100Mo 99Tc Half-Life: 66 Hours Half-Life: 6 Hours STABLE Half-Life: 6 Hours © ASP Isotopes Inc. 14
Slide 15: Geopolitical Tailwinds for ASPI Nuclear Medicine
Geopolitical Tailwinds for ASPI Nuclear Medicine World’s Largest Nuclear Facilities Manufacturing Isotopes 1. Government Support for Alternative Supply “Between 95 and 98 percent of 99Mo is currently being produced using highly enriched uranium (HEU) targets, which was the major concern of Congress.
Slide 16: Silicon-28: Enabling Quantum Computing
Silicon-28: Enabling Quantum Computing Quantum Computers are expected to be 1000x more powerful than today’s conventional computers and are widely anticipated to create new opportunities in medicine, artificial intelligence, cybersecurity, finance, logistics, and other industries. The semiconductor
Slide 17: Market Opportunities of Other Isotopes
Market Opportunities of Other Isotopes For Use in Quantum Computing For Use in Oncology 1. Quantum computing requires ultra-pure Silicon-28 1. Ytterbium-176 is emerging as a better method of Which is not available at any price at commercial producing Lutetium-177, which is an emerging scale therapeu
Slide 18: Future Growth Plans to Scale ASPI Business into new Isotopes
Future Growth Plans to Scale ASPI Business into new Isotopes Iceland identified as the likely optimal location for expansion: Iceland Electricity Network • Iceland’s policy is to attract high-tech green industry into the country to support its own long-held ESG-based ethos. • Likely government suppo
Slide 19: © ASP Isotopes Inc.
ae IANTUM LEAP ENERGY ASP isotopes) ©
Slide 20: The Equation is a Well-Known Fact... Solving it is not Straightforward
The Equation is a Well-Known Fact... Solving it is not Straightforward Global Electricity Production needs to double by 2050. Protesting is not going to Solve … The Solution Requires the Equation… Innovation and Investment At the same time, the world needs to achieve carbon neutrality. © ASP Isotope
Slide 21: The Global Necessity for Increased Green Nuclear Energy
The Global Necessity for Increased Green Nuclear Energy Increasing Demand for Energy Security Increasing Focus on Energy Nuclear Power By Country ▪ To reach Net Zero emissions by ▪ Russia is responsible for 35% of ▪ UK plans to build 8 new nuclear power 2050, the world must increase enriched uranium
Slide 22: Nuclear Power Uptake Benefits
Nuclear Power Uptake Benefits Low Carbon Energy Constant and Cost Competitive Essential Energy Controllable Energy Energy Diversity Nuclear power is one of the Nuclear power provides Nuclear power provides Renewable energies world's energy sources that continuous electricity continuous electricity (
Slide 23: SMR (Small Modular Reactors) = Next Wave in Nuclear Energy
SMR (Small Modular Reactors) = Next Wave in Nuclear Energy The world is moving to a new type of nuclear reactor: SMR TerraPower’s Natrium ▪ Modular, smaller size (50 MWe to 300 MWe) reactors allowing greater flexibility in deployment ▪ Designed for production-line manufacturing rather than conventio
Slide 24: HALEU Supply Issue Looming for SMR Reality
Annual US Demand Growth for HALEU HALEU Supply Issue 700 Looming for SMR Reality 600 500 ▪ Current commercial LWRs use low-enriched uranium 400 (LEU) which has less than 5% 235U content. 300 ▪ Many SMRs and advanced reactors will require High 200 Assay Low Enriched Uranium (HALEU) with 235U enrichme
Slide 25: Comparing and Contrasting Enrichment Methods
Comparing and Contrasting Enrichment Methods Atomic Vapor Laser Molecular Laser Isotope Quantum Enrichment Gaseous Diffusion Centrifugation Isotope Separation Silex Systems Separation (MLIS) (used by QLE) (AVLIS) Capital 1/10 of Cost High capital cost Low Capital, small size Low Capital, small size
Slide 26: What is Quantum Enrichment?
What is Quantum Enrichment? ▪ Quantum Enrichment was derived from AVLIS (Atomic Vapor Laser Isotope Separation). Isotopes of every element also have unique spectroscopic “signatures” defined by the electromagnetic radiation or “light” absorbed by their atoms from electron transitions. ▪ Quantum enri
Slide 27: Nuclear Fuel Cycle
Nuclear Fuel Cycle Estimated World Primary Conversion Capacity 2020 Estimated World Primary Enrichment Capacity 2020 Nameplate Capacity Capacity 2020 Capacity (Thousand Company Country Location Country Company and Plant Capacity (tU) Utilization (%) Utilization (tU) SWU/yr) Orano France Pierrelatte
Slide 28: Nuclear Fuel Prices are at 10-Year Highs
Nuclear Fuel Prices are at 10-Year Highs • Multiple Macroeconomic factors caused by geopolitics, pandemics, blocked canals, and weather, have caused long-term Uranium price indicators to continue to rise to 10-year highs. • Front-end nuclear fuel markets highlight numerous and increasing risks facin
Slide 29: Current Implications of Depleted UF6 tails
Current Implications of Depleted UF6 tails Depleted tails from other Uranium enrichers produce nuclear waste. The management of this waste is becoming a problem. Our Process has the ability to process this waste into HALEU Potentially providing a solution to this growing environmental problem Deplet
Slide 30: Production Profile – Next 10+ Years
Production Profile – Next 10+ years • The company initially expects to process low-enriched uranium (LEU) as a feedstock. This allows us to rapidly increase the production volumes to meet the near-term demand of our customers. A laser system produces substantially more HALEU when using LEU as a feed
Slide 31: Investment Thesis
Investment Thesis 1. Proven & Proprietary Technology ASPI's advanced technology platform leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Its innovative technology will enable the company to manufacture a diverse range of isotopes, which will meet the growing de
Slide 32: Management Team
Management Team © ASP Isotopes Inc. 32
Slide 33: ASP Isotopes: Leadership Team
ASP Isotopes: Leadership Team PAUL MANN SERGEY VASNETSOV HENDRIK STRYDOM, PhD Chairman, and CEO Vice-Chairman of the Board Director, Chief Technology Officer ▪ Co-founded ASP Isotopes in ▪ Founder and Managing Director ▪ Co-developer of “Aerodynamic September 2021 of ChemBridges, strategy Separation
Slide 34: ASP Isotopes: Scientific Advisors
ASP Isotopes: Scientific Advisors EINAR RONANDER Chief Scientific Advisor ▪ Globally recognized as a leading scientist in the field of isotope separation for medical and industrial applications ▪ Pioneered the Molecular Laser Isotope Separation (MLIS) and the Atomic Vapour Laser Isotope Separation (
Slide 35: ASP Isotopes: Non-Executive Directors
ASP Isotopes: Non-Executive Directors DUNCAN MOORE, PhD TODD WIDER, MD JOSHUA DONFELD Director Director Director ▪ Partner at East West Capital ▪ Executive Chairman and Chief ▪ 20+ years Investing experience Partners, specializing in Medical Officer, Emendo on Wallstreet investment opportunities wit
Slide 36: Data Sources
Data Sources 1. Wang, Yiwei et al. “Production Review of Accelerator-Based Medical Isotopes.” Molecules (Basel, Switzerland) vol. 27,16 5294. 19 Aug. 2022, doi:10.3390/molecules27165294. 2. B.L. Zhukov et al. "Production of medical radionuclides in Russia: Status and future - a review.” Applied Radi